UEG's educational platform for gastroenterology education bringing recordings, courses, guidelines, and more together in one place.

UEG Week Berlin 2025 Recordings Gut Guide online

Rate for better recommendations!

Your feedback helps us show you more of what you like and less of what you dislike!

More of this!

We will show you more similar content.

Not for me!

We won't suggest this again.

Bookmark!

Save this content for later!

New to myUEG? Create an account! Log In with myUEG account

UEG Poster

Standard Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Free for all myUEG account holders. Your access level is set automatically based on your occupation. Medical professionals get full access to all content. If you are a non-medical user, you can only access UEG Week content from congresses you attended.

Not sure what you can access? Learn more about account types.

Introduction

Obtaining adequate tissue samples in subepithelial lesions (SELs) remains challenging. Several biopsy techniques are available, but a systematic review including all available techniques to obtain a histological diagnosis of SEL is lacking. The aim of this study is to evaluate the diagnostic yield and complication rates of endoscopic biopsies, EUS-FNA, EUS-FNB and MIAB for SELs in the upper gastro-intestinal tract.

Aims & Methods

A search strategy in multiple databases was performed. The primary outcome was diagnostic yield, defined as the percentage of procedures where histology was obtained and resulted in a definitive histopathological diagnosis. Secondary outcome measures included reported procedure-related adverse events which were classified according to the Clavien-Dindo classification.

Results

A total of 94 original papers were included. Studies were classified per endoscopic technique to obtain histopathology. This resulted in 8 included studies for endoscopic biopsy methods, 55 studies for FNA, 33 studies for FNB and 26 studies for MIAB. Pooled rates for diagnostic yield were 40.6% (95% CI 30.8-51.2%) for endoscopic biopsy, 74.6% (95% CI, 69.9-78.7%) for EUS-FNA, 84.2% (95% CI 80.7-87.2%) for EUS-FNB, 88.2% (95% CI 84.7-91.1%) for MIAB. Notable heterogeneity was seen. Reported procedure-related complications graded Clavien-Dindo 2 or more were 2.8-3.9% for endoscopic biopsies, 1.0-4.5% for EUS-FNA, 1.2-7.7% for EUS-FNB, 1.9-6.7% for MIAB.

Conclusion

Based on the available evidence, MIAB and EUS-FNB seem to be most effective in terms of achieving a high diagnostic yield, with similar rates of adverse events.

DIAGNOSTIC YIELD OF ENDOSCOPIC AND EUS-GUIDED BIOPSY TECHNIQUES IN SUBEPITHELIAL LESIONS OF THE UPPER GASTRO-INTESTINAL TRACT: A SYSTEMATIC REVIEW AND META-ANALYSIS

Cynthia Verloop 1, Jacqueline Goos 2, Marco J. Bruno 3, Rutger Quispel 4, Lydi van Driel 5, lieke Brouwer-Hol 1

1 Maasstad Hospital Rotterdam, Rotterdam, Netherlands

2 IJsselland hospital, Capelle aan den IJssel, Netherlands

3 University Medical Center Rotterdam, Rotterdam, Netherlands

4 Reinier de Graaf Gasthuis, Delft, Netherlands

5 Erasmus Medical Center, Schiedam, Netherlands

Conference

UEG Week Copenhagen 2023

Topics

Oesophagus

Submission format

Abstract

Session

Endoscopy and beyond (Posters)

Citation

United European Gastroenterology Journal 2023; 11 (Supplement 8)

Published

2023

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Not sure what you can access? Learn more about account types.

Pancreatic cancer - a rising problem. Surgical, oncological and endoscopic treatment, screening modalities for early detection

Ioannis S Papanikolaou 1

1 Attikon University Hospital, National and Kapodistrian University of Athens, Medical School., Athens, Greece

Event

UEG Week Berlin 2025

Topics

Nurses

Session

Patient care: Differences matter

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

UEG Presentation

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Not sure what you can access? Learn more about account types.

ERPC

Thierry Ponchon 1

1 Edouardo Herriot University Hospital, Lyon, France

Event

UEG Week Vienna 2024

Topics

Digestive Oncology Endoscopy Hepatobiliary Pancreas

Session

Mistakes in …: Hepatobiliary and pancreas

Citation

United European Gastroenterology Journal 2024; 12 (Supplement 8)

Published

2024

UEG Poster

Standard Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Not sure what you can access? Learn more about account types.

Introduction

Transjugular intrahepatic portosystemic shunt (TIPS) is a well-established interventional treatment for complications of portal hypertension. Post-TIPS transient or persistent acute bilirubin elevation (ABE) is common, possibly due to impairment of portal perfusion. The outcomes of patients with ABE is not clear.

Aims & Methods

This study investigates the incidence, clinical outcomes, and prognostic factors associated with ABE in cirrhotic patients undergoing TIPS. Between January 2009 and November 2022, 1,287 patients (882 men, 405 women; mean age, 52 years) were included in this retrospective analysis. ABE was defined as a total serum bilirubin level exceeding 85.5 μmol/L (5 mg/dL) within one week after TIPS. Statistical analyses included the Kaplan-Meier method, log-rank test, multivariate Cox regression, and stepwise regression.

Results

Post-TIPS ABE occurred in 67 patients (5.2%). Patients with ABE had significantly higher baseline Child-Pugh scores (8.39 ± 1.62 vs. 7.41 ± 1.54, P < 0.001) and MELD scores (13.98 ± 4.13 vs. 10.72 ± 2.99, P < 0.001). Refractory ascites as the TIPS indication was more frequent in the ABE group (17.91% vs. 7.21%, P = 0.001). ABE was associated with a significantly higher incidence of hepatic encephalopathy (HE): 62.7% vs. 38.3% at 1 year and 80.6% vs. 62.8% at 5 years (P = 0.042). During follow-up, 441 patients died, with causes including liver failure (n = 129), gastrointestinal bleeding (n = 100), sepsis (n = 16), multi-organ dysfunction (MOD) (n = 41), hepatocellular carcinoma (HCC) (n = 43), and other or unknown causes (n = 112). Survival rates were significantly lower in the ABE group: 1-year (52.2% vs. 85.2%), 3-year (34.3% vs. 68.3%), and 5-year (25.4% vs. 46.6%) (P < 0.001). Multivariate analysis identified ABE (hazard ratio [HR]: 2.09; 95% confidence interval [CI]: 1.41–3.10; P < 0.001), age (HR: 1.05; 95% CI: 1.04–1.06; P < 0.001), albumin level (HR: 0.95; 95% CI: 0.94–0.97; P < 0.001), pre-TIPS grade 4 HE (HR: 1.93; 95% CI: 1.19–3.14; P = 0.008), presence of HCC (HR: 1.81; 95% CI: 1.24–2.65; P = 0.002), baseline MELD score (HR: 1.09; 95% CI: 1.04–1.14; P < 0.001), and change in MELD score (HR: 1.08; 95% CI: 1.06–1.11; P < 0.001) as independent predictors of post-TIPS mortality.

Conclusion

AEB is not rare in cirrhotic patients undergoing TIPS and is associated with an increased risk of HE and mortality. Risk factors for post-TIPS mortality include AB, older age, higher and fluctuating MELD scores, concurrent HCC, severe pre-TIPS HE, and lower albumin levels. Early identification, close monitoring, and prompt management of complications are essential to improving clinical outcomes and reducing the risk of liver failure after TIPS.

INCIDENCE, RISK FACTORS, AND OUTCOMES OF ACUTE BILIRUBIN ELEVATION FOLLOWING TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT CREATION

Xuefeng Luo 1, Peiling Gan 1

1 Westchina Hospital, Chengdu, China

Conference

UEG Week Berlin 2025

Topics

Hepatobiliary

Submission format

Abstract

Session

Updates in portal hypertension and cirrhosis management (Posters)

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

UEG Poster

Standard Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Not sure what you can access? Learn more about account types.

Introduction

Chronic liver disease remains one of the most common causes for hospital admission and is associated with high morbidity and mortality rates. Timely and adequate management within the first 24 hours is crucial for improving clinical outcomes in cases of decompensated cirrhosis. This study aimed to evaluate the impact of implementing a care bundle checklist during the first 24 hours of hospital admission on management and outcomes of decompensated cirrhosis.

Aims & Methods

We developed an adapted care bundle (based on the BSG/BASL care bundle, AASLD quality measures proposal, Baveno VII consensus, and EASL guidelines) and compared two patient groups from two Portuguese hospital centers: Group-A (retrospective, pre-care bundle implementation) and Group-B (prospective, post-care bundle implementation).

Results

A total of 224 patients (Group-A: 148; Group-B: 76) were included. More than one decompensation was observed in 118 patients (52.7%), and 69 patients (30.8%) were experiencing their index hospitalization for liver decompensation. Regarding etiology, alcoholic liver disease was the most common (n=200; 89.3%). The groups were similar in terms of gender, age, length of hospital stay, and Child-Pugh and MELD-Na scores at admission. The most common decompensations were gastrointestinal bleeding (n=91; 40.6%), ascites (n=75; 33.5%), and hepatic encephalopathy (n=72; 32.1%). Group B was more likely to present with multiple decompensations at admission and exhibited significantly higher rates of acute kidney injury, hepatocellular carcinoma, acute-on-chronic liver failure, and portal vein thrombosis (p<0.05). Following care bundle implementation, we found significant improvements in patient care. At admission, patients were significantly more likely to undergo urine and blood cultures, chest X-ray, and abdominal ultrasound (p<0.05), receive diagnostic paracentesis (p<0.05), and have an accurate alcohol history documented (p=0.04). During admission, Group-B was significantly more likely to be prescribed lactulose for encephalopathy prophylaxis, vasopressor therapy for gastrointestinal bleeding, and venous thromboembolism prophylaxis, as well as undergo nutritional assessment (p<0.05). While in-hospital mortality rates were similar (4.7% vs. 5.3%; p=1), 6-week mortality rates (8.8% vs. 3.9%; p=0.01) and 3-month readmission rates (31.1% vs. 15.8%; p=0.02) were significantly lower in the post-intervention cohort.

Conclusion

The implementation of a standardized care bundle was associated with higher rates of appropriate investigation and treatment within the first 24 hours of hospital admission and improved patient outcomes, reducing 6-week mortality and 3-month readmission rates.

ENHANCING OUTCOMES IN DECOMPENSATED CIRRHOSIS: A MULTICENTER STUDY ON THE IMPACT OF A CARE BUNDLE APPROACH

Luís Santos 1, Rita Regatia 2, Mara Costa 1, Inês Costa Santos 3, Claudia Agostinho 1, Dario Gomes 4, Ana Oliveira 3, Pedro Narra Figueiredo 4

1 Unidade Local de Saúde de Coimbra, Coimbra, Portugal

2 Portuguese Oncology Institute of Coimbra, Coimbra, Portugal

3 Unidade Local de Saúde da Arrábida, Setúbal, Portugal

4 Unidade Local de Saúde de Coimbra, Coimbra, Portugal|||Faculty of Medicine, University of Coimbra, Coimbra, Portugal

Conference

UEG Week Berlin 2025

Topics

Hepatobiliary

Submission format

Abstract

Session

LIVER (Posters)

Citation

United European Gastroenterology Journal 2025; 13 (Supplement 8)

Published

2025

UEG Poster

Standard Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Not sure what you can access? Learn more about account types.

Introduction

Inflammatory Bowel Diseases (IBD) patients are associated to a higher risk of developing colonic dysplasia and colorectal cancer due to long-standing colonic inflammation and immunosuppressant therapies. They seem to have also a higher risk of developing extra-intestinal malignancies, such as cholangiocarcinoma, skin cancer, and others. Different studies have been conducted to assess whether a correlation exists between IBD, medical treatments and cancers, but the results are controversial.

Aims & Methods

Our study aimed to evaluate the risk factors of malignancies in our IBD patients, particularly considering the medication history.
In this single-center retrospective study, IBD patients with a history of at least one malignancy post-IBD diagnosis followed at the Gastroenterology Unit of Azienda Ospedale Università Padova were enrolled (cases). Demographics and clinical data, including medication information, were collected before and at the time of malignancy diagnosis. A group of IBD patients, matched by sex and age, without a malignancy history were also included (controls), considering the medications taken before and at the time of the last visit for comparison.

Results

Among 2213 IBD patients followed at our center (1212 males, 1040 CD, and 1173 UC), 153 cases (80 UC and 73 CD, 46.4% males, mean age at diagnosis: 38.4±14.7) and 50 sex and matched controls were included (30 UC and 20 CD, 52% males, mean age at diagnosis: 38.9±0.8). Twelve patients had two malignancies, and 2 had three. For the scope of our study, we considered only the first tumor. Results are shown in the Table 1. The mean time from IBD diagnosis to the first tumor was 15 years (SD 10.5). Considering malignancies, the most frequent in our population were breast cancer (27/1001 females, 2.7%), colorectal cancer (23/2213, 1%), melanoma (24/2213, 1.1%), and non-melanoma skin cancer (15/2213, 0.7%). Patients with colon cancer were younger at the time of IBD diagnosis (31.0±15.8 vs. 38.9±0.8), while patients with prostate and urinary cancer (11/2213, 0.5%) were older compared to controls (49.6±13.7 vs. 38.9±0.8). A lower percentage of patients with colon (13%), breast (4%), and prostate cancers (9.1%) had taken biological therapy before cancer occurrence, as compared to controls (44%, p<0.01). Finally, we observed a significantly higher number of melanoma and breast cancer patients taking azathioprine (AZA) at the time of cancer diagnosis for more than 4 years. No difference in terms of duration of AZA and biological therapies before cancer diagnosis was observed.

Table 1: Type and frequency of Malignancies and characteristics of the patients

	Colon	Lymphoma	Melanoma	Non-melanoma	Breast	Urinary	Prostate
N	23 cases	9 cases	24 cases	15 cases	27 cases	12 cases	11 cases
Age at the time of cancer	52.7±16.4	59±11.6	49.4±12.9	54.1±11.0	55.9±12.4	56.1±15.4	65.3±8.5
Gender (Males,%) Cases Controls	14 (60.9) 26 (52)	5 (55.6) 26 (52)	12 (50) 26 (52)	7 (46.7) 26 (52)	0*** 26 (52)	11 (91.6)** 26 (52)	11 (100)** 26 (52)
Age at cancer diagnosis (mean ± SD) Cases Controls	31.0±15.8*** 38.9±0.8	41.2±14.1 38.9±0.8	38.2±15.6 38.9±0.8	38.1±13.3 38.9±0.8	40.9±13.9 38.9±0.8	44.9±15.7** 38.9±0.8	49.6±13.7*** 38.9±0.8
Type of Disease (UC%) Cases Controls	12 (52.2) 30 (60)	5 (55.5) 30 (60)	12 (50) 30 (60)	8 (53.3) 30 (60)	11 (40.7) 30 (60)	7 (58.3) 30 (60)	7 (58.3) 30 (60)
Biologic before Cases Controls	6 (26.1) 17 (34)	17 (34)	9 (37.5) 17 (34)	8 (53.3) 17 (34)	8 (29.6) 17 (34)	3 (25) 17 (34)	1 (9.1) 17 (34)
AZA before Cases Controls	6 (26.1) 13 (26)	6 (66.7) 13 (26)	10 (41.7) 13 (26)	6 (40) 13 (26)	9 (33.3) 13 (26)	2 (16.7) 13 (26)	2 (18.2) 13 (26)
Biologic ongoing Cases Controls	3 (13.0)** 22 (44)	7 (87.5) 22 (44)	7 (29.2) 22 (44)	5 (33.3) 22 (44)	4 (14.8)** 22 (44)	2 (16.7) 22 (44)	1 (9.1)** 22 (44)
AZA ongoing Cases Controls	0 0	0 0	3 (12.5)** 0	1 (6.7) 0	4 (14.8)** 0	0 0	0 0

Other cancers: Cholangiocarcinoma (1), thyroid (8), lung (5), uterus&ovary (5); other (13) *** p<0.001, ** p<0.01, and * p<0.05.

Conclusion

Our study found that biological therapy was not associated to malignancies, while azathioprine use was associated with breast and melanoma cancers. A younger age at diagnosis was associated with colon cancer, while an older age with prostate and urinary cancers.

RISK FACTORS OF MALIGNANCIES IN INFLAMMATORY BOWEL DISEASE: A SINGLE CENTER EXPERIENCE

Daria Maniero 1, Domenico Castaldo 1, Luisa Bertin 1, Brigida Barberio 1, Edoardo Vincenzo Savarino 1, Fabiana Zingone 1

1 University of Padova, Padova, Italy

Conference

UEG Week Copenhagen 2023

Topics

IBD

Submission format

Abstract

Session

PP 05 IBD (Posters)

Citation

United European Gastroenterology Journal 2023; 11 (Supplement 8)

Published

2023

UEG Poster

Standard Poster

Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Not sure what you can access? Learn more about account types.

Introduction

With the increase in the opportunity to follow up patients with risk factors for pancreatic cancer, such as IPMN, using imaging tests, it is generally considered to discontinue follow-up for those who are elderly and not eligible for surgery. There are few studies comparing the group of patients who underwent surgery with those who did not undergo surgery among super-elderly individuals aged 80 years or older.

Aims & Methods

This was a retrospective, single-center study aimed at examining the extension of survival by surgery in healthy super-elderly patients aged 80 years and over with pancreatic cancer. Among the 183 patients diagnosed with histologically confirmed conventional ductal adenocarcinoma of the pancreas at our hospital between April 2011 and March 2021, we targeted 20 cases aged 80 years or older, whose clinical courses were available, and who were considered to be resectable or borderline resectable with an ECOG Performance Status of 0. Of the 20 cases, 11 underwent surgery and 9 did not, and we retrospectively compared the surgery group and non-surgery group.

Results

The age of the surgery group was 83±5 years, while that of the non-surgery group was 88±6 years, which was significantly higher in the non-surgery group. However, there was no significant difference in gender, symptom rate, abdominal pain rate, or blood test results for Alb, AMY, CEA, or CA19-9 levels. Tumor localization was pancreatic head (64%), pancreatic body (18%), and pancreatic tail (18%) in the surgery group, while all cases in the non-surgery group were located in the pancreatic head. All cases in the surgery group were Resectable on CT imaging, and they underwent pancreaticoduodenectomy (73%), distal pancreatectomy (18%), or total pancreatectomy (9%) without NeoAdjuvant Chemotherapy. In the non-surgery group, 89% were Resectable and 11% were Borderline on CT imaging, and the reasons for non-resection were age (45%), patient preference (33%), past medical history (11%), and surgeon's judgment (11%). Chemotherapy was administered in 64% of the surgery group and 67% of the non-surgery group, and second-line or later treatment was administered in 27% of the surgery group and 22% of the non-surgery group. In addition, radiation therapy was administered in 18% of the surgery group. The median survival time (IQR) was 333 (251-426.5) days in the surgery group and 226 (137-728) days in the non-surgery group, which was significantly longer in the surgery group. All cases in the surgery group died of the original disease, while 78% of the non-surgery group died of the original disease and 22% died of cerebral infarction.

Conclusion

Surgery is expected to prolong the survival period even in super-elderly individuals, and imaging follow-up for early detection of pancreatic cancer is important even in super-elderly individuals if they have a surgical tolerance.

CONSIDERATION OF WHETHER SCREENING FOR EARLY DETECTION OF PANCREATIC CANCER SHOULD BE CONTINUED EVEN IN SUPER-ELDERLY INDIVIDUALS

Ryo Kodama 1, Yusuke Oka 1, Yoshiaki Kobayashi 1, Yukiko Yokota 1, Hisanobu Saegusa 1, Hiroyasu Ushimaru 1

1 Minaminagano Medical Center, Shinonoi General Hospital, Nagano, Japan

Conference

UEG Week Copenhagen 2023

Topics

Pancreas

Submission format

Abstract

Session

PP 08 Pancreas (Posters)

Citation

United European Gastroenterology Journal 2023; 11 (Supplement 8)

Published

2023

UEG's educational platform for gastroenterology education bringing recordings, courses, guidelines, and more together in one place.

Most popular content

Rate for better recommendations!